Primary outcome: adverse events (assessed at 3 months as minimum, moderate or severe) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost of the intervention · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported
Investigator‐ or physician‐rated global assessment of disease severity · People with erosive oral lichen planus
Betamethasone oral mini-pulse therapy led to higher physician Global Assessment (clinical severity, 0-12 score) compared with topical triamcinolone acetonide 0.1% paste; GRADE not reported.
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by a decrease in total inflammatory lesion count, measured in participants who were treated for a minimum period of 16 weeks (Changes from baseline in total inflammatory lesion count and number of participants... · participants with moderate and severe acne
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by physician's global evaluation 20 to 24 weeks · participants with moderate and severe acne
1 finding from 1 review